 Houston Museum of Natural Science CEO Joel A. Bartsch has a passion for international travel and world history. Joel Bartsch is particularly interested in traveling to the Middle East and experiencing the culture.
The Middle East nation Saudi Arabia has been inhabited for tens of thousands of years and has many historical landmarks, including six UNESCO heritage sites. The city of Jubbah is home to one of the oldest rock carvings, also known as petroglyphs, in the world. Some of the images date back to 10,000 BC. The most recent carvings, phrases from an ancient language, were written in 3,000 BC. Archeologists believe that Jubbah was once a green oasis with a settled population. The images in the rocks depict scenes from daily life. Visitors can learn how residents in the ancient civilization dressed and the types of animals living in the area. Due to the fragile nature of the petroglyphs, tourists can only visit the Jubbah site with an approved tour.
0 Comments
 Joel A. Bartsch serves as president and CEO of the Houston Museum of Natural Science, Houston, Texas, in 2021. He has restructured the organization and increased its profits. Joel Bartsch earned his master’s in history of science from Rice University, an institution known for its artificial heart research.
Rice University is a research university located in Houston, Texas. The school prides itself in pursuing pathbreaking research and fostering innovative collaborations. Rice University offers applied science programs in structural chemical analysis, signal processing, nanotechnology, space science, and artificial heart research. Artificial heart research has been on for decades. Nonetheless, it has proven quite challenging to build an artificial heart that copies a real heart for a long time without causing infections or blood clots. In 2018, MIT Technology Review reported that the SynCardia developed heart was the only artificial one available in the United States. This heart was supposed to be a temporary support for patients while they await a heart transplant. More recently, in January 2021, the FDA allowed Carmat Artificial Heart's use in an early feasibility study. Carmat believes that their heart will offer a therapeutic substitute to heart transplants for people suffering from heart failure. |
AuthorMuseum Executive Joel Bartsch. Archives
March 2022
Categories
All
|
RSS Feed
